Products for Research Use Only

PI3K/mTOR-IN-19

CAT: 0804-HY-179155Size: 1 EachDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-179155Size:1 Each
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
PI3K/mTOR-IN-19 is an orally active, potent, selective PI3K (IC50 = 4.23 nM) and mTOR (IC50 = 2.3 nM) inhibitor. PI3K/mTOR-IN-19 significantly inhibits Eca109 cell viability and induces apoptosis. PI3K/mTOR-IN-19 causes G0/G1 cell cycle arrest, decreased mitochondrial membrane potential, and demonstrates marked telomerase inhibitory activity. PI3K/mTOR-IN-19 modulates the expression of key apoptotic regulators (Bcl-2, Bax, and p53) and downregulates the PI3K/Akt/mTOR signaling pathway. PI3K/mTOR-IN-19 can be used for the study of esophageal cancer[1].
UNSPSC
12352005
Target
Apoptosis; Bcl-2 Family; MDM-2/p53; Mitochondrial Metabolism; mTOR; PI3K; Telomerase
Related Pathways
Apoptosis; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; PI3K/Akt/mTOR
Field of Research
Cancer; Inflammation/Immunology
Smiles
O=C(OCCN(CC)CC)C1=CC=C(N2N=NC(C3=NOC(C4=CC=C(F)C=C4)=C3)C2C)C=C1
Molecular Formula
C25H28FN5O3
Molecular Weight
465.52
References & Citations
[1]Sheng Y, et al. Design, synthesis, and biological evaluation of procaine-based triazole-isoxazoline hybrids as selective PI3K/mTOR inhibitors for esophageal cancer therapy: in vitro and in vivo studies. RSC Med Chem. 2025 Oct 15.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
Bax; Bcl-2; mTOR; PI3K